Is Syncom Formul. overvalued or undervalued?
As of November 18, 2025, Syncom Formul. is fairly valued with a PE ratio of 24.53, compared to its peers like Sun Pharma at 36.56 and Cipla at 22.49, indicating reasonable pricing relative to its earnings growth potential despite underperforming the Sensex year-to-date.
As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued.In comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
